ORIGINAL RESEARCH article

Front. Child Adolesc. Psychiatry, 07 December 2022

Sec. Autism and Other Neurodevelopmental Disorders

Volume 1 - 2022 | https://doi.org/10.3389/frcha.2022.987339

Genetic analysis of neurodevelopmental disorders in children

  • Child Healthcare Department, Children's Hospital of Nanjing Medical University, Nanjing, China

Article metrics

View details

4

Citations

5,7k

Views

1,2k

Downloads

Abstract

Purpose:

To explore the genetic cause of children with unidentified etiology of neurodevelopmental disorders, thus providing references for the diagnosis, treatment and genetic counseling.

Design and methods:

Children with neurodevelopmental disorders but unidentified etiology in the Child Healthcare Department, Children's Hospital of Nanjing Medical University from November 2018 to December 2021 were retrospectively analyzed. A total of 2 ml of peripheral venous blood was collected from the child and their parents for the whole exome sequencing (WES) and copy number variation (CNV) detection. Male children were subjected to fragile X syndrome testing to determine the genetic mutations. For those with positive results, Sanger sequencing was performed to explore the mutations in the gene sites and pedigrees.

Results:

A total of 488 (33.5%) pathogenic variations were detected among 1,457 global developmental/intellectual disabilities (GDD/ID) children, including 362 (24.9%) cases of monogenic mutations, and 111 (7.6%) cases of chromosomal microdeletions or microduplications. There were 15/780 (1.92%) male children with fragile X syndrome. Single point mutations were detected in 277/362 (76.5%) and 85/362 (23.5%) male and female GDD/ID children, respectively, including 295 (81.5%) cases of missense mutations, 32 (8.8%) cases of frameshift mutations, 5 (2.2%) cases of non-sense mutations and 30 (8.3%) cases of splice site mutations. In addition, there were 166 (45.8%) cases of autosomal inheritance and 196 (54.2%) cases of X-linked inheritance. The X chromosome abnormalities were mostly observed in 362 GDD/ID children with monogenic mutations, including 15 cases of the AFF2 gene mutation, 13 cases of the MECP2 gene mutation and 12 cases of the HUWEI gene mutation. The CREBBP gene mutation was the most common autosome abnormality in GDD/ID children with monogenic mutations, which was detected in five cases. There were 74 cases of chromosomal microdeletions, 31 cases of chromosomal microduplications and six cases of both. A total of 114 novel pathogenic mutations responsible for GDD/ID were found, including four novel mutations in MECP2 and TRAPPC9 genes.

Conclusion:

The incidence of genetic abnormalities remains high in NDD children. Abundant novel mutations are responsible for GDD/ID in children, and can be used as references in the diagnosis of neurogenetic diseases.

Introduction

Neurodevelopmental disorders (NDD), an array of multifactorial chronic diseases, seriously impair children's physical and psychological health, even cross their lifespan. NDD include at least global developmental/intellectual disabilities (GDD/ID), autism spectrum disorders (ASD), both as main contributors to pediatric disability worldwide. GDD/ID exhibit highly heterogeneous clinical and genetic features, often complicated with ASD and attention deficit and hyperactivity disorder (ADHD) [1]. ID has a global prevalence of 1%, and serious ID of 0.6%. ASD was first reported in 1943, with a global incidence ever-growing to 1% in 2012 according to the WHO data [24].

NDD are caused by environmental and genetic factors. In an era with updating livelihood and enriching medical resources, exogenous factors, like infection, poisoning, trauma, hypoxia, malnutrition, illiteracy, psychological impairment, have been well-uncovered and controlled. In contrast, genetic factors remain enigmatic by large. About 2/3 of ID are caused by genetic factors, including chromosome abnormality, single or multiple-gene mutation, or inborn errors of metabolism. With plural manifestations, ID meets with no effective treatments, leading to a high rate of disability. Special education or rehabilitation training may alleviate ID symptoms, but their application across the lifespan is restricted by a huge cost [58].

Genetic diagnosis and counseling can benefit the treatment of NDD children, even prevent secondary adverse pregnancy outcomes. In the present study, a total of 1,457 GDD/ID and ASD children with unidentified etiology were collected and analyzed with the whole exome sequencing (WES). For those with positive results, Sanger sequencing was performed to explore the mutations in the gene sites and pedigrees. Male children were subjected to fragile X syndrome testing to determine the genetic mutations. Our findings are expected to provide references for the diagnosis and treatment of children with GDD/ID or ASD.

Materials and methods

Setting and participants

We recruited 1,457 children treated for GDD/ID and ASD of unclear etiology from November 2018 to December 2021 at the Department of Children Health Care, Children's Hospital of Nanjing Medical University (Nanjing, China), including 1,152 males (79.1%) and 305 females (20.9%). Inclusion criteria were as follows: (1) Assessment of GDD/ID. Gesell Developmental Scales (Gesell) [9], Griffiths Development Scales-Chinese Edition (GDS-C) [10], Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV) [11], Wechsler Intelligence Scale for Children (WISC-IV) [12], and Infants-Junior Middle School Student's Social-Life Abilities Scale (S-M scale) [13] were adopted to assess GDD/ID in children. Children with two or more domains of Gesell and GDS-C that were significantly lower than those in children of the same age (>2 standard deviations) were assessed as GDD. WPPSI-IV and WISC-IV were used to assess GDD/ID in children with 2.5–6 and 6–16 years, respectively. According to the intelligence quotient (IQ) range and social adaptability, ID was classified into mild (IQ: 50–69), moderate (IQ: 35–49), severe (IQ: 20–34), and profound (IQ <20). Corresponding developmental assessment scales were used according to the developmental level and age of children (Table 1). (2) Assessment of ASD. The Autism Behavior Checklist (ABC) [14] and the Childhood Autism Rating Scale (CARS) [15] were adopted to assess autism symptoms in children. ASD was diagnosed in children with the total ABC score ≥67 points and CARS score ≥30 points.

Table 1

AgeDevelopmental assessment scales
0–3 yearsGesell
3–6 yearsGDS-C (non-verbal children)
WPPSI-IV+ S-M scale
6–8 yearsGDS-C (non-verbal children)
WISC-IV+ S-M scale
>8 yearsWISC-IV + S-M scale

Corresponding developmental assessment scales for GDD/ID children at different ages.

GDD/ID, global development disabilities/intellectual disabilities; Gesell, Gesell Developmental Scales; GDS-C, Griffiths Development Scales-Chinese Edition; WPPSI-IV, Wechsler Preschool and Primary Scale of Intelligence; S-M scale, Infants-Junior Middle School Student's Social-Life Abilities Scale; WISC-IV, Wechsler Intelligence Scale for Children.

Exclusion criteria: (1) children with specific genetic diseases and genetic metabolic diseases diagnosed by clinical symptoms and signs, and laboratory testing; (2) children with GDD/ID and ASD caused by perinatal ischemia, hypoxic brain injury, bilirubin encephalopathy, and central nervous system infection, poisoning and trauma.

Procedures

After obtaining the written informed consent of the guardians, 2 ml of peripheral venous blood was collected from each child and his/her parents for WES and CNV detection. Male children were subjected to fragile X syndrome testing to determine the genetic mutations. For those with positive results, Sanger sequencing was performed to explore the mutations in the gene sites and pedigrees.

Target capture sequencing (TCS)

DNA fragments of the target region were enriched by microarray hybridization, then subjected to the next-generation high-throughput sequencing. In the present study, the exon regions of 23,000 genes were captured using the Gen Cap custom exome enrichment kit (My Genostics, Beijing, China). Briefly, genomic DNA fragments were ligated to the Illumina-supplied adapter sequences, then subjected to ligation-mediated polymerase chain reaction (LM-PCR). After amplification and purification, the quality of DNA library was checked. PCR products were hybridized with the target capture microarray, and the captured sequence was analyzed using the Illumina Nova 6000 sequencer (Illumina, San Diego, CA, USA). Raw data were processed for image recognition and differentiation.

Bioinformatic analyses

After trimming adapter sequences from short read data, the Illumina sequencing reads were mapped to the human reference genome (GRCh37/hg19, 2009 Assembly) using the BWA-MEM alignment algorithm of Burrows-Wheeler Aligner (BWA, http://bio-bwa.sourceforge.net) [16, 17]. Single nucleotide variation (SNV) and inserts and deletions (INDEL) were analyzed using the Genome Analysis Toolkit (GATK, http://software.broadinstitute.org) [18], and annotated by ANNOVAR (http://annovar.openbioinformatics.org/en/latest/) [19]. Mutation sites with a frequency of <0.05 were screened out of the following databases, including the 1,000 Genomes Project (http://www.1000genomes.org), Exome Variant Server (http://evs.gs.washington.edu) and EXAC (http://exac.broadinstitute.org/). Pathogenicity and conservative prediction of missense mutations were carried out using SIFT (http://sift.jcvi.org/) [2022], PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) [2325], MutationTaster (http://www.mutationtaster.org/) [26], and GERP++ (http://mendel.stanford.edu/SidowLab/downloads/gerp/index.html) [27]. Changes in splice sites were analyzed for pathogenicity using SPIDEX (http://www.openbioinformatics.org/annovar/spidex_download_form.php).

PCR and sanger sequencing

Mutations of interest were subjected to PCR and Sanger sequencing. PCR primers were synthesized using Primer 3.0 (http://primer3.ut.ee/) [2830]. In addition, PCR products were subjected to Sanger sequencing and analyzed using the ABI 3130 Genetic Analyzer (Applied Biosystems), followed by the family cosegregation analysis.

Fragile X syndrome testing

DNA extracted from peripheral blood was analyzed by PCR, and the PCR fragment was designed to flank the area of repeats and effectively adjust the size of the PCR product correspondingly to the repeat size. After allele-specific methylation PCR, capillary electrophoresis was performed to measure the number of CTG repeats.

Statistical analysis

Data were expressed as medians and interquartile ranges (IQRs), and processed using SPSS 22.0. P < 0.05 was considered as statistically significant.

Results

Types of pathogenic variations

There were 1,253/1,457 (85.9%) children with GDD/ID and 204/1,457 (14.1%) with GDD/ID and autism. A total of 488 (33.5%) pathogenic variations were detected among 1,457 GDD/ID children, including 362 (24.9%) monogenic mutations, and 111 (7.6%) chromosomal microdeletions or microduplications. Fifteen male children (1.92%, 15/780) aged 2–13 years presented with fragile X syndrome, and four of their mothers were determined as premutation carriers, while FMR1 premutation was not detected in their fathers. Notably, full mutation in FMR1 gene was detected in 9 male children of 4 pedigrees (Table 2).

Table 2

CharacteristicsNumber of patients (%)
Total1,457
Sex
Male1,152 (79.1%)
Female305 (20.9%)
Age
≤ 1 year402 (27.6%)
>1 year, ≤ 3 years753 (51.7%)
>3 year, ≤ 6 years231 (15.9%)
>6 year71 (4.8%)
Genetic etiology
CGG repeat expansion in the FMR1 gene15 (1.0%)
Small pathogenic variations362 (24.9%)
Pathogenic CNVs111 (7.6%)
Total488 (33.5%)

Baseline characteristics of GDD/ID children.

GDD/ID, global development disabilities/intellectual disabilities; CNV, copy number variation.

Monogenic mutations in GDD/ID children

Common monogenic mutations responsible for GDD/ID

Most of the X chromosome abnormalities were observed in 362 GDD/ID children with monogenic mutations, including 15 with AFF2 gene mutation, 13 with MECP2 gene mutation and 12 with HUWEI gene mutation. The CREBBP gene mutation, detected in five cases, was the most common autosome abnormality in GDD/ID children with monogenic mutations (Table 3).

Table 3

GeneInheritance patternNumber of patients (%)Number of male patients (%)Number of female patients (%)
AFF2XLR15 (1.03%, 15/1,457)13 (1.13%, 13/1,152)2 (0.66%, 2/305)
MECP2XL13 (0.89%, 13/1,457)6 (0.52%, 6/1,152)7 (2.23%, 7/305)
HUWEIXL12 (0.82%, 12/1,457)11 (0.95%, 11/1,152)1 (0.33%, 1/305)
BRWD3XLR10 (0.69%, 10/1,457)11 (0.95%, 11/1,152)0
ATRXXL6 (0.4%, 6/1,457)5 (0.43%, 5/1,152)1 (0.33%, 1/305)
DLG3XLR5 (0.34%, 5/1,457)5 (0.43%, 5/1,152)0
ZNF41XL5 (0.34%, 5/1,457)5 (0.43%, 5/1,152)0
PTCHD1XLR5 (0.34%, 5/1,457)5 (0.43%, 5/1,152)0
CREBBPAD5 (0.34%, 3/1,457)3 (0.26%, 3/1,152)2 (0.66%, 2/305)

Pathogenic variations in GDD/ID children.

GDD/ID, global development disabilities/intellectual disabilities; XLR, X-linked recessive inheritance; XL, X-linked inheritance; AD, autosomal dominant inheritance.

Single point mutations in GDD/ID children

Monogenic mutations were detected in 362 GDD/ID children, involving 277 males and 85 females. Among them, 295 carried missense mutations, 32 carried frameshift mutations, five carried non-sense mutations, and 30 carried splice site mutations (Table 4). In particular, non-sense mutations were inherited in 3 GDD/ID children with an autosomal recessive pattern, involving 1 combined with splice site mutation and 2 with frameshift mutations.

Table 4

Mutation typeNumber of patients (%)Number of male patients (%)Number of female patients (%)
Missense mutation295 (81.5%, 295/362)237 (85.6%, 237/277)58 (68.2%, 58/85)
Frameshift mutation32 (8.8%, 32/362)16 (5.6%, 16/277)16 (18.8%, 16/85)
Nonsense mutation5 (1.4%, 5/362)0 (0%, 0/277)5 (5.9%, 5/85)
Splice site mutation30 (8.3%, 30/362)24 (8.7%, 24/277)6 (7.1%, 6/85)

Single site mutations in GDD/ID children.

GDD/ID, global development disabilities/intellectual disabilities.

Novel single point mutations in GDD/ID children

Newly discovered single point mutations were abundant in 362 cases of GDD/ID children, all never reported before. The mutations were considered pathogenic (P) based on protein damage due to mutation-induced premature termination codon and clinical manifestations of affected children. Moreover, their pathogenicity (p) was considered as positive results from more than four online tools in predicting the pathogenicity of rare missense variants (e.g., SIFT, PolyPhen_2MutationTaster, GERP++, and REVEL). At last, 114 novel pathogenic mutations responsible for GDD/ID were found (Table 5).

Table 5

Patient IDGeneInheritance patternCDS changeAmino-acid changeZygosityPatho-genicityOrigi-n
Case 1POMT1ARNM_007171
c.1624T>G
p.F542VhetaPhMatf
POMT1ARNM_007171
c.1901_1902insGCG
CTGGGTGCTGGC
TGGG
p.C643Gfs*94hetaPgDnd
Case 2ZSWIM6ADNM_020928
c.1033+1G>T
SplicinghetaPhDnd
Case 3DCXXLNM_000555
c.982G>T
p.D328YhemibPhMatf
Case 4THOC2XLRNM_001081550
c.4237G>T
p.D1413YhemibPhMatf
Case 5MBD5ADNM_018328
c.1472G>T
p.R491MhetaPhMatf
Case 6OTCXLRNM_000531
c.1024C>A
p.L342MhemibPhMatf
Case 7DLG3XLRNM_021120
c.2351T>C
p.I784ThemibPhMatf
Case 8MAN2B1ARNM_000528
c.2993G>A
p.R998HhetaPhMatf
MAN2B1ARNM_000528
c.748G>T
p.A250ShetaPhPate
Case 9SMC1AXLDNM_006306
c.673C>T
(p.L225F)hemibPhMatf
Case 10PRSS12ARNM_003619
c.905delG
p.G302fs*15hetaPgMatf
PRSS12ARNM_003619
c.2476G>A
p.G826RhetaPhPate
Case 11IL1RAPL1XLRNM_014271
c.1033G>A
p.A345ThemibPhMatf
Case 12HUWE1XLNM_031407
c.10930G>A
(p.E3644K)hemibPhMatf
Case 13STAG2XLNM_001042749
c.403A>G
(p.M135V)hemibPhMatf
Case 14SCN8AADNM_014191
c.2130A>C
(p.E710D)hetaPhMatf
Case 15CASKXLDNM_003688
c.62G>A
(p.G21D)hemibPhMatf
Case 16SMC1AXLDNM_006306
c.3362G>A
p.R1121HhetaPhDnd
Case 17DYNC1H1ADNM_001376
c.5684C>A
(p.A1895D)hetaPhDnd
Case 18FBXO11ADNM_001190274
c.1421T>G
(p.I474R)hetaPhDnd
Case 19CAMK2AADNM_015981
c.74C>T
p.S25LhetaPhDnd
Case 20HUWE1XLNM_031407
c.1708C>A
p.P570ThemibPhDnd
Case 21SCN2AADNM_021007
c.809T>G
p.F270ChetaPhDnd
Case 22CTCFADNM_006565
c.950C>G
(p.T317R)hetaPhDnd
Case 23SATB2ADNM_001172509,
c.1942C>T
p.L648FhetaPgDnd
Case 24HCN1ADNM_021072
c.1082A>G
p.Y361ChetaPgDnd
Case 25GRIN2BADNM_000834
c.2108A>C
p.H703PhetaPgDnd
Case 26SMC3ADNM_005445
c.3520A>G
p.T1174AhetaPgDnd
Case 27MECP2XLDNM_004992
c.397C>T
p.R133ChemibPgDnd
Case 28MECP2XLNM_001110792
c.916C>T
p.R306XhemibPgDnd
Case 29CREBBPADNM_004380
c.4883A>G
p.H1628RhetaPgDnd
Case 30PCNTARNM_006031
c.8997-1G>A
-homcPgMatf+Pate
Case 31TCF4ADNM_001083962
c.1727G>A
p.R576QhetaPgDnd
Case 32IGF1RARNM_000875
c.1949G>A
p.R650QhetaPhMatf
IGF1RARNM_000875
c.2894G>A
p.S965NhetaPhPate
Case 34KMT2AADNM_001197104
c.3634+1G>C
-hetaPgDnd
Case 35PAFAH1B1ADNM_000430
c.193-2A>T
-hetaPgDnd
Case 36DDX3XXLNM_001193416
c.1582C>T
p.R528ChemibPgDnd
Case 37TRIOADNM_007118
c.4024G>A
p.G1342RhetaPgDnd
Case 38PPP2R1AADNM_014225
c.656C>T
p.S219LhetaPgDnd
Case 39SLC6A19ARNM_001003841
c.985G>A
p.A329ThetaPhMatf
SLC6A19ARNM_001003841
c.1213G>A
p.E405KhetaPhPate
Case 40CTCFADNM_006565
c.1102C>T
p.R368ChetaPgDnd
Case 41KCNQ3ADNM_004519
c.689G>A
p.R230HhetaPgDnd
Case 42DLG3XLRNM_020730
c.58delT
p.S20Pfs*45hemibPgMatf
Case 43CC2D1AARNM_017721
c.1941-5G>A
SplicinghetaPhMatf
CC2D1AARNM_017721
c.2342G>T
p.G781VhetaPhPate
Case 44BRWD3XLRNM_153252
c.4591G>A
p.G1531RhemibPhMatf
Case 45KDM5CXLRNM_004187
c.1843G>C
p.V615LhemibPhMatf
Case 46MECP2XLNM_004992
c.378-8_378-
19delTTTCT
GTTTGTC
SplicinghemibPhMatf
Case 47NLG N4XXLNM_020742
c.1612C>A
p.Q538KhemibPgMatf
Case 48AFF2XLRNM_0011 70628
c.26C>T
p.A9VhemibPgMatf
Case 49SHANK2XLNM_133266
c.1651G>A
p.E551KhetaPgMatf
Case 50ASXL3ADNM_030632
c.1533_1534del
p.L512Afs*4hetaPgDnd
Case 51SHROOM4XLNM_020717
c.722G>A
p.R241QhemibPgMatf
Case 52PGAP2ARNM_001256240
c.493C>T
p.R165WhetaPgDnd
PGAP2ARNM_001256240
c.590C>T
p.A197VhetaPhMatf
Case 53TRAPPC9ARNM_031466
c.2314T>A
p.L772MhetaPgPate
TRAPPC9ARNM_001160372
c.1981+3A>G
SplicinghetaPgMatf
Case 54THOC2XLRNM_001081550
c.275-7A>G
SplicinghemibPgMatf
Case 55TINF2ADNM_001099274
c.953_956delTGG
GinsCGG
p.MG318TfshetaPgPate
Case 56FOXRED1ARNM_017547
c.608_609delAG
p.E203fs*16hetaPgPate
FOXRED1ARNM_017547
c.395C>T
p.A132VhetaPgMatf
Case 57HUWE1XLNM_031407
c.5521-6T>G
SplicinghemibPgMatf
Case 58MED12XLRNM_005120
c.4416-3T>C
SplicinghemibPgMatf
Case 59NLGN4XXL, IC, MuNM_020742
c.2104_2105dupAA
p.R704fs*32hemibPgMatf
Case 60BPTFADNM_004459
c.4413_4414delTG
p.C1471XhetaPgMatf
Case 61IQSEC2XLDNM_015075
c.12dupC
p.G5Rfs*23hemibPgMatf
Case 62ASXL3ADNM_030632
c.4798C>T
p.Q1600XhetaPgDnd
Case 63BRWD3XLRNM_153252
c.3481+6A>G
SplicinghemibPgMatf
Case 64NHLRC2ARNM_198514
c.950T>C
p.I317ThomcPgMatf+Pate
Case 65QRICH1ADNM_017730
c.1740G>A
p.W580XhetaPgDnd
Case 66BCORL1XLRNM_021946
c.4946C>T
p.T1649IhemibPgMatf
Case 67SOX4ADNM_003107
c.309_c.311delCGA
p.D104delhetaPgDnd
Case 68KMT2CADNM_170606
c.5777_5778del
p.C1926Yfs*8hetaPgDnd
Case 69SHANK3ADNM_033517
c.4727dupT
p.A1578Gfs*102hetaPgDnd
Case 70CTNNB1ADNM_001904
c.1830delC
p.Q611Kfs*3hetaPgDnd
Case 71FLNAXLDNM_001456
c.987+1G>A
SplicinghetaPgDnd
Case 72ZBTB18ADNM_205768
c.583C>T
p.R195XhetaPgDnd
Case 73PPM1DADNM_003620
c.1303_1306dupCATA
p.I436Tfs*8hetaPgDnd
Case 74BCL11BADNM_138576
c.1946_1967delGCGC
GGTCAACGGGCGC
GGGGG
p.G649Afs*67hetPgDnd
Case 75SETD5ADNM_001080517
c.675C>A
p.Y225XhetaPgDnd
Case 77DDX3XXLR, XLDNM_001193416
c.1616-1G>T
SplicinghetaPgDnd
Case 78CREBBPADNM_004380
c.6324C>G
p.Y2108XhetaPgDnd
Case 79CD96ADNM_198196
c.1006_1010delGTTTT
p.V336fs*5hetaPgDnd
Case 80AUTS2ADNM_015570
c.1946G>A
p.W649XhetaPgDnd
Case 81DYNC1H1ADNM_001376
c.4401_4405delAGAAG
p.R1467Sfs*6hetaPgDnd
Case 82GATAD2BADNM_020699
c.1195_1196del
p.Q399Efs*4hetaPgDnd
Case 83KMT2AADNM_001197104
c.502_502+1delGGinsC
SplicinghetaPgDnd
Case 84CTNNB1ADNM_001904
c.1973dupT
p.L659Ffs*6hetaPgDnd
Case 85SHANK2-NM_133266
c.3412_3413del
p.L1138V fs*16hetaPgDnd
Case 86SCN2AADNM_021007
c.5704delC
p.R1902Afs*20hetPgDnd
Case 87BRWD3XLRNM_153252
c.4081-8_4081-6delCTT
SplicinghetaPgDnd
Case 88CACNA1CADNM_000719
c.396_399delGACT
p.T133Ffs*8hetaPgDnd
Case 89PHF21AADNM_001101802
c.1703delA
p.K568Sfs*9hetaPgDnd
Case 90ASXL2ADNM_018263
c.2930_2934delTGAAA
p.M977Nfs*24hetaPgDnd
Case 91MED13ADNM_005121
c.4552delT
p.S1518Qfs*16hetaPgDnd
Case 92FOXG1ADNM_005249
c.896delT
p.F299Sfs*27hetaPgDnd
Case 93CREBBPADNM_004380
c.2608C>T
p.Q870XhetaPgDnd
Case 94ZNF292ADNM_015021
c.4414C>T
p.R1472XhetaPgDnd
Case 95ANKRD11ADNM_013275
c.4617_4618delGA
p.K1540Rfs* 13hetaPgDnd
Case 96CTCFADNM_006565
c.737delT
p.G247Vfs*2hetaPgDnd
Case 97HSD17B10XLDNM_004493
c.748G>A
p.V250IhemibPhMatf
Case 98TRAPPC9ARNM_031466
c.1781C>T
p.S594LhetaPhMatf
TRAPPC9ARNM_031466
c.80C>G
p.S27ChetaPhPate
Case 99IQSEC2XLDNM_001111125
c.1104G>T
p.E368DhemibPhMatf
Case 100AFF2XLRNM_002025
c.1358A>G
p.Q453RhemibPhMatf
Case 101AFF2XLRNM_002025
c.1084C>T
p.R362WhemibPhMatf
Case 102MED12XLRNM_005120
c.5584C>T
p.R1862ChemibPhMatf
Case 103GRIA3XLRNM_000828
c.425G>A
p.R142HhemibPhMatf
Case 104NLGN3XL, IC, MUNM_018977
c.290G>A
p.R97QhemibPhMatf
Case 105CACNA1AADNM-001127221
c.4989C>G
p.F1663LhetaPhDnd
Case 106ZDHHC9XLNM_016032
c.137T>G
p.L46RhemibPhMatf
Case 107FTSJ1XLRNM_012280
c.557G>A
p.R186QhemibPhDnd
Case 108SONADNM_032195
c.514A>G
p.R172GhetaPhDnd

Novel single point mutations in GDD/ID children.

a

het, heterozygosity.

b

hemi, hemizygosity.

c

homo, homozygosity.

d

Dn, de novo.

e

Pat, paternal.

f

Mat, maternal.

g

P, pathogenic.

h

p, pathogenicity predicted to be positive in more than 4 online tools for predicting the pathogenicity of rare missense variants (e.g., SIFT, PolyPhen_2MutationTaster, GERP++, and REVEL).

GDD/ID, global development disabilities/intellectual disabilities; AR, autosomal recessive; AD, autosomal dominant inheritance; XL, X-linked inheritance; XLR, X-linked recessive inheritance; XLD, X-linked dominant inheritance.

Inheritance patterns of single point mutations in GDD/ID children

Among the 362 GDD/ID children with single point mutations, 166 (45.8%) presented with autosomal inheritance, and 196 (54.2%) presented with X-linked inheritance (Table 6).

Table 6

Inheritance patternNumber of patients (%)Number of male patients (%)Number of female patients (%)
AD125 (34.5%, 125/362)82 (30.7%, 85/277)43 (50.6%, 43/85)
AR41 (11.3%, 41/362)27 (9.7%, 27/277)14 (16.5%, 14/85)
XD51 (14.1%, 51/362)32 (11.6%, 32/277)19 (22.4%, 19/85)
XR145 (40.1%, 145/362)136 (49.1%, 136/277)9 (10.6%, 9/85)

Inheritance patterns of the single site mutations in GD/IDD children.

GDD/ID, global development disabilities/intellectual disabilities; AD, autosomal dominant inheritance; AR, autosomal recessive; XD, X-linked dominant inheritance; XR, X-linked recessive inheritance.

Chromosomal microdeletions or microduplications

We identified 74 children with chromosomal microdeletions, 31 with chromosomal microduplications and 6 with both. Among the 111 (7.6%) cases of chromosomal microdeletions or microduplications, we detected 16 cases of Williams syndrome (WS), four cases of Phelan-McDermid syndrome (22q13 deletion syndrome), four cases of Prader-Willi syndrome or Angelman syndrome with deletions or duplications at the 15q11.2q13.1 locus (Table 7).

Table 7

Number of patients (%)Number of male patients (%)Number of female patients (%)
Microdeletion74 (66.7%, 74/111)41 (74.5%, 41/55)33 (58.9%, 33/56)
Microduplication31 (27.9%, 31/111)13 (23.6%, 13/55)18 (32.1%, 18/56)
Microdeletion and microduplication6 (5.4%, 6/111)1 (1.8%, 1/55)5 (8.9%, 5/56)

Pathogenic CNVs in GD/IDD children.

CNV, copy number variation; GDD/ID, global development disabilities/intellectual disabilities.

Discussion

Clinical manifestations of NDD in children are diverse, the disability rate of which remains high. However, effective treatment for NDD lacks. Genetic factors are predominantly responsible for NDD, including chromosomal abnormalities, single or multiple gene mutations and congenital metabolic defects. In the present study, 362 (24.9%) pathogenic mutations were found in 1,457 GDD/ID children, dominated by missense mutation (295/362, 81.5%).

We found abundant single site mutations in GDD/ID children that have not been previously reported, and 114 of them were confirmed as pathogenic, including 51 (44.7%) of autosomal dominant, 21 (18.4%) of autosomal recessive, 8 (7.0%) of X-linked dominant, 18 (15.8%) of X-linked recessive and 16 (14.0%) of X-linked. Among them, 54 (47.4%) were inherited from parents, and 60 (52.6%) were spontaneous mutations. The latter was considered to pose a stronger destructive effect on biological functions than genetic mutations. Our findings provide valuable clinical evidence supporting the genetic causes of sporadic GDD/ID in children.

The newly discovered mutations in GDD/ID children have expanded the genetic spectrum of this disease. Notably, four novel mutations were found in MECP2 and TRAPPC9 genes, respectively. A total of seven female GDD/ID children carrying MECP2 gene presented obvious intellectual disability and stereotyped behavior. MECP2 gene is also the second most common gene for sex-linked genetic diseases. With the discovery of novel mutation sites, the incidence of neurodevelopmental disorders caused by MECP2 gene is estimated to increase [31]. Novel mutations in the TRAPPC9 gene were detected in 3 GDD/ID children. Notably, a GDD/ID child carried two novel mutations in the TRAPPC9 gene with the clinical manifestations of severe intellectual disability and autism. NIBP/TRAPPC9 mutations are associated with non-syndromic autosomal recessive intellectual disability (NS-ARID), which is known as NIBP syndrome, and assigned as the intellectual disability-obesity-brain malformations facial dysmorphism syndrome in the human disease database Mala Cards [32].

All included GDD/ID children received WES and CNV detection. Chromosomal abnormalities and genomic microdeletions and microduplications act as critical genetic causes for NDD in children. In the present study, a total of 111 (7.6%) children with pathogenic CNVs were detected, involving 74 (66.7%) with microdeletions, 16 (27.9%) with microduplications and 6 (5.4%) with both. The incidence of microdeletions was much higher than that of microduplications in GDD/ID children. Theoretically, the incidence of genomic microdeletions is close to that of microduplications. In the early stage of gamete formation, however, neither duplication nor deletion is prone to occur. It is reported that the phenotype of microduplication is often milder (no clinical phenotype occurs) than that of microdeletion. Even at the chromosomal level, triploids are more likely to survive than haploids [3335]. WS, a 7q11.23 duplication syndrome, was the most common disorder in GDD/ID children. Our findings differed from the previous studies of microdeletion or microduplication, which may be linked with the bigger data in our institution.

Sex-linked genetic diseases are characterized by an obvious between-sex difference. Healthy females can carry pathogenic genes of X-linked dominant and recessive disorders, bringing with a high risk of genetic diseases inherited through the pedigree. Among 1,457 GDD/ID children, we detected 196 (54.1%), 51 (14.1%), and 145 (40.1%) children X-linked inheritance, X-linked dominant inheritance, and X-linked recessive inheritance, respectively. The incidence of X-linked inheritance was similar to that of autosomal inheritance. However, X-linked recessive inheritance is more recessive and harmful. Chromosome positioning of 473 GDD/ID children carrying definite pathogenic genes showed that the X chromosome was the most common position of gene abnormalities. Consistently, the top 3 pathogenic genes (the AFF2, MECP2, and HUWEI gene) in GDD/ID children were also located in the X chromosome.

AFF2 gene (OMIM 300806) maps to Xq28 and is highly expressed in brain regions involved in learning, cognition, and memory, including the hippocampus and amygdala. Murine AFF2 has an 88% amino acid similarity with human AFF2. In situ hybridization of adult mouse brains showed labeling in the cingulate gyrus, hippocampus, piriform cortex, and Purkinge layers [36, 37].

The expansion of CCG trinucleotide in the AFF2 gene causes a form of X-linked intellectual disability (ID) related to Fragile site E (FRAXE) at Xq28. The clinical presentations of FRAXE fragility vary a lot, including mild intellectual disability, learning disabilities, communication deficits, attention deficit hyperactivity disorder (ADHD), and autistic spectrum. Translocations disrupting AFF2, partial or entire deletions and partial duplication have been described in ID patients. Partial AFF2 deletions, especially smaller deletions, are usually associated with a milder phenotype or autism, whereas complete loss of gene function causes FRAXE. A partial AFF2 duplication has been reported associated with mild ID [3840].

In addition, Fragile X syndrome is inherited with an X-linked incomplete dominance, manifested as hereditary intellectual disability and autism. Mainly caused by the dynamic (CGG)n mutation, it develops with the silence or severe downregulation of Fragile X intellectual disability protein (FMRP). Fragile X syndrome is considered as the most common cause of intellectual disability in men in Europe and North America, which is observed in 10–20%. The prevalence of a full mutation of FMR1 in the general population and females is 1/4,000–1/5,000 and 1/4,000–1/8,000, respectively. A large-scale screening of Fragile X syndrome in 51,000 newborns of mainland China in 2021 has shown that the frequencies of CGG repeats >100 in males and females are 1/9,371 and 1/5,887, respectively. In addition, the premutation rate of Fragile X syndrome in the Chinese population is lower than that in Caucasians [41]. In the present study, 15/780 (1.9%) of male GDD/ID children were diagnosed as Fragile X syndrome. Notably, the full mutation in the FMR1 gene was detected in nine male children in four pedigrees.

Neurodevelopmental and psychiatric disorders are a highly heterogeneous group of developmental and mental disorders, resulting from the complex interaction between genetic and environmental factors and leading to various disabilities. The diagnosis of neurodevelopmental disorders is challenging, due to its multifactor, comorbidity and polygenicity. Its genetic mechanism has been firmly established, but the its causative variants remain to be discovered. At present, new tools, such as WES, have unearthed an increasing number of genetic variants responsible for human diseases.

In the present study, we performed the genetic analysis of neurodevelopmental disorders in 1,457 children from Jiangsu and Anhui Provinces, China, and provided etiological diagnosis and genetic consultation to 488 (33.5%) cases with identified pathogenic mutations. Our study provides references for prenatal diagnosis, thus preventing adverse reproductive outcomes. In addition, we found 114 novel pathogenic mutations responsible for GDD/ID, which expanded the genetic spectrum of GDD/ID. The TRAPPC9 gene was not familiar with neurodevelopmental disorders, but showed 4 mutations in GDD/ID children. More neurodevelopment-associated loci in the TRAPPC9 gene may be discovered in the future. In addition, the incidence of Fragile X syndrome in 488 children with identified pathogenic mutations was lower than those of AFF2 (3.6%) and HUWEI (3.0%) in male GDD/ID children. Our findings are different from the previous that Fragile X syndrome is the second leading cause of male ID, which may be attributed to the genetic variations in different races. AFF2 gene is closely linked with FRAXE, which was also the top pathogenic gene in the present study. Here, a total of 30 (2.1%) GDD/ID children presented both AFF2 gene mutation and Fragile X syndrome. Sex-linked genetic diseases are the main cause of neurodevelopmental disorders in children, especially in males. Newborn screening of AFF2 gene and Fragile X syndrome is recommended for early diagnosis and intervention of potential genetic diseases, especially for those high-risk families.

The genetic background of one disease varies much across China with a large population and 56 ethnicities. Rich dada about various genetic diseases have accumulated in medical institutions around China. However, a large-scale or state-level biological sample database has not been built up. Current research on genetic diseases is usually limited in Jiangsu and Anhui Provinces, China. Multi-center cohort studies of genetic diseases should be conducted in the future to further improve the diagnosis and treatment of neurogenetic diseases.

Limitation

Some limitations in this study should be noted. First, all GDD/ID children were from Nanjing and surrounding regions. Second, they were all Han Chinese and we did not recruited subjects an ethnic minority. Our findings should be further validated in the large-scale study involving multiple ethnic minorities.

Statements

Data availability statement

The raw sequence data reported in this paper have been deposited in the Genome Sequence Archive (Genomics, Proteomics & Bioinformatics 2021) in National Genomics Data Center (Nucleic Acids Res 2022), China National Center for Bioinformation/Beijing Institute of Genomics, Chinese Academy of Sciences (GSA-Human: HRA003395) that are publicly accessible at https://ngdc.cncb.ac.cn/gsa-human.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of Children's Hospital of Nanjing Medical University (202110083-1). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

Author contributions

RL designed the study and helped write the manuscript. DW performed the interpreted data and wrote the manuscript. All authors contributed to the article and approved the submitted version.

Acknowledgments

The authors gratefully acknowledge the contributions of the doctors and nurses in the Nanjing Children's Hospital and the participation of the child and his parents.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1.

    LecomteJMercierC. The WHO atlas on global resources for persons with intellectual disabilities: a right to health perspective. Salud Publica Mex. (2008) 50(Suppl.2):s1606. 10.1590/S0036-36342008000800009

  • 2.

    FriedmanA. Outdated language: use of “Mental Retardation” in medicaid HCBS waivers post-Rosa's Law. Intellect Dev Disabil. (2016) 54:34253. 10.1352/1934-9556-54.5.342

  • 3.

    MaennerMJBlumbergSJKoganMDChristensenDYeargin-AllsoppMSchieveLA. Prevalence of cerebral palsy and intellectual disability among children identified in two U.S. National Surveys, 2011-2013. Ann Epidemiol. (2016) 26:2226. 10.1016/j.annepidem.2016.01.001

  • 4.

    Beadle-BrownJMansellJGarcía-IbañezJMagallanesTNovellRPooleMet al. Intellectual disability in Europe: overview. In: European Intellectual Disability Research Network, editor, Intellectual Disability in Europe. Working Papers. (2003). p. 111.

  • 5.

    MaYChenCWangYWuLHeFZhangCet al. Analysis copy number variation of Chinese children in early-onset epileptic encephalopathies with unknown cause. Clin Genet. (2016) 90:42836. 10.1111/cge.12768

  • 6.

    VissersLEGilissenCVeltmanJA. Genetic studies in intellectual disability and related disorders. Nat Rev Genet. (2016) 17:918. 10.1038/nrg3999

  • 7.

    ChiurazziPPirozziF. Advances in understanding - genetic basis of intellectual disability. F1000Res. (2016) 5:1. 10.12688/f1000research.7134.1

  • 8.

    O'ByrneJJLynchSATreacyEPKingMDBettsDRMaynePDet al. Unexplained developmental delay/learning disability: guidelines for best practice protocol for first line assessment and genetic/metabolic/radiological investigations. Ir J Med Sci. (2016) 185:2418. 10.1007/s11845-015-1284-7

  • 9.

    JinXSunYJiangFMaJMorganCShenX. “Care for Development” intervention in rural China: a prospective follow-up study. J Dev Behav Pediatr. (2007) 28:2138. 10.1097/dbp.0b013e31802d410b

  • 10.

    CirelliMBickle GrazATolsaJF. Comparison of Griffiths-II and Bayley-II tests for the developmental assessment of high-risk infants. Infant Behav Dev. (2015) 41:1725. 10.1016/j.infbeh.2015.06.004

  • 11.

    WatkinsMWBeaujeanAA. Bifactor structure of the Wechsler Preschool and Primary Scale of Intelligence–Fourth Edition. Sch Psychol Q. (2014) 29:5263. 10.1037/spq0000038

  • 12.

    BaronIS. Test review: Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV). Child Neuropsychol. (2005) 11:4715. 10.1080/09297040590951587

  • 13.

    JiCYaoDChenWLiMZhaoZ. Adaptive behavior in Chinese children with Williams syndrome. BMC Pediatr. (2014) 14:90. 10.1186/1471-2431-14-90

  • 14.

    KaatAJLecavalierLAmanMG. Validity of the aberrant behavior checklist in children with autism spectrum disorder. J Autism Dev Disord. (2014) 44:110316. 10.1007/s10803-013-1970-0

  • 15.

    RelliniETortolaniDTrilloSCarboneSMontecchiF. Childhood Autism Rating Scale (CARS) and Autism Behavior Checklist (ABC) correspondence and conflicts with DSM-IV criteria in diagnosis of autism. J Autism Dev Disord. (2004) 34:7038. 10.1007/s10803-004-5290-2

  • 16.

    LiHDurbinR. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. (2009) 25:175460. 10.1093/bioinformatics/btp324

  • 17.

    LiHDurbinR. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. (2010) 26:58995. 10.1093/bioinformatics/btp698

  • 18.

    McKennaAHannaMBanksESivachenkoACibulskisKKernytskyAet al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. (2010) 20:1297303. 10.1101/gr.107524.110

  • 19.

    WangKLiMHakonarsonH. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. (2010) 38:e164. 10.1093/nar/gkq603

  • 20.

    ChoiYSimsGEMurphySMillerJRChanAP. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE. (2012) 7:e46688. 10.1371/journal.pone.0046688

  • 21.

    ChoiY. A fast computation of pairwise sequence alignment scores between a protein and a set of single-locus variants of another protein. Bioinformat Comput Biol. (2012) 2012:2382989. 10.1145/2382936.2382989

  • 22.

    ChoiYChanAP. PROVEAN. web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics. (2015) 31:27457. 10.1093/bioinformatics/btv195

  • 23.

    AdzhubeiAJordanDMSunyaevSR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. (2013) 7:20. 10.1002/0471142905.hg0720s76

  • 24.

    RamenskyBorkPSunyaevS. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. (2002) 30:3894900. 10.1093/nar/gkf493

  • 25.

    SunyaevSREisenhaberFRodchenkovIVEisenhaberBTumanyanVGKuznetsovENet al. Profile extraction from sequence alignments with position-specific counts of independent observations. Protein Eng. (1999) 12:38794. 10.1093/protein/12.5.387

  • 26.

    SchwarzJMCooperDNSchuelkeMSeelowD. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. (2014) 11:3612. 10.1038/nmeth.2890

  • 27.

    UntergasserACutcutacheIKoressaarTYeJFairclothBCRemmMet al. Primer3–new capabilities and interfaces. Nucleic Acids Res. (2012) 40:e115. 10.1093/nar/gks596

  • 28.

    KoressaarTRemmM. Enhancements and modifications of primer design program Primer3. Bioinformatics. (2007) 23:128991. 10.1093/bioinformatics/btm091

  • 29.

    KoressaarTLepametsMKaplinskiLRaimeKAndresonRRemmM. Primer3_masker: integrating masking of template sequence with primer design software. Bioinformatics. (2018) 34:19378. 10.1093/bioinformatics/bty036

  • 30.

    CooperGMStoneEAAsimenosGGreenEDBatzoglouSSidowA. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res. (2005) 15:90113. 10.1101/gr.3577405

  • 31.

    ChahilGBolluPC. Rett Syndrome. Treasure Island: StatPearls (2022).

  • 32.

    AmbergerJSBocchiniCAScottAFHamoshA. OMIM.org: leveraging knowledge across phenotype-gene relationships. Nucleic Acids Res. (2019) 47:D103843. 10.1093/nar/gky1151

  • 33.

    PanigrahiJainPDidelSAgarwalSMuthuswamySSahaAet al. Identification of microdeletion and microduplication syndromes by chromosomal microarray in patients with intellectual disability with dysmorphism. Neurol India. (2018) 66:13706. 10.4103/0028-3886.241346

  • 34.

    MostovoyYYilmazFChowSKChuCLinCGeigerEAet al. Genomic regions associated with microdeletion/microduplication syndromes exhibit extreme diversity of structural variation. Genetics. (2021) 217:iyaa038. 10.1093/genetics/iyaa038

  • 35.

    MohammadzadehAAkbaroghliSAghaei-MoghadamEMahdiehNBadvRSJamaliPet al. Investigation of chromosomal abnormalities and microdeletion/ microduplication(s) in fifty iranian patients with multiple congenital anomalies. Cell J. (2019) 21:33749. 10.22074/cellj.2019.6053

  • 36.

    TakataA. Estimating contribution of rare non-coding variants to neuropsychiatric disorders. Psychiatry Clin Neurosci. (2019) 73:2. 10.1111/pcn.12774

  • 37.

    ServettiMPisciottaLTassanoECerminaraMNobiliLBoeriSet al. Neurodevelopmental disorders in patients with complex phenotypes and potential complex genetic basis involving non-coding genes, and double CNVs. Front Genet. (2021) 12:732002. 10.3389/fgene.2021.732002

  • 38.

    MondalKRamachandranDPatelVCHagenKRBosePCutlerDJet al. Excess variants in AFF2 detected by massively parallel sequencing of males with autism spectrum disorder. Hum Mol Genet. (2012) 21:435664. 10.1093/hmg/dds267

  • 39.

    RKCYMericoDBookmanMThiruvahindrapuramBPatelRV. Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. Nat Neurosci. (2017) 20:60211. 10.1038/nn.4524

  • 40.

    DeneaultEWhiteSHRodriguesDCRossPJFaheemMZaslavskyKet al. Complete disruption of autism-susceptibility genes by gene editing predominantly reduces functional connectivity of isogenic human neurons. Stem Cell Reports. (2018) 11:121125. 10.1016/j.stemcr.2018.10.003

  • 41.

    ZhangJYWuDWYangRLZhuLJiangMYWangWJet al. FMR1 allele frequencies in 51,000 newborns: a large-scale population study in China. World J Pediatr. (2021) 17:6538. 10.1007/s12519-021-00473-6

Summary

Keywords

neurodevelopmental disorders, global developmental/intellectual disabilities, autism spectrum disorders, children, gene

Citation

Wu D and Li R (2022) Genetic analysis of neurodevelopmental disorders in children. Front. Child Adolesc. Psychiatry 1:987339. doi: 10.3389/frcha.2022.987339

Received

06 July 2022

Accepted

21 September 2022

Published

07 December 2022

Volume

1 - 2022

Edited by

Sara Calderoni, Stella Maris Foundation (IRCCS), Italy

Reviewed by

Maria Pia Pia Riccio, Federico II University Hospital, Italy; Alessandra Carta, University of Sassari, Italy

Updates

Copyright

*Correspondence: Rong Li

This article was submitted to Autism and Other Neurodevelopmental Disorders, a section of the journal Frontiers in Child and Adolescent Psychiatry

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics